Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Natural Products Journal, The
  4. Volume 15, Issue 3
  5. Article
Volume 15, Issue 3
  • ISSN: 2210-3155
  • E-ISSN: 2210-3163

Abstract

Background and Objective

Prior research indicates that disruptions in melatonin secretion levels and timing could be linked to the pathophysiology of bipolar disorder. Our study aimed to assess the effectiveness of melatonin as an adjunctive therapy to classical mood stabilizers in addressing sleep impairment and mood symptoms in bipolar patients currently experiencing manic episodes.

Methods

Fifty-eight hospitalized patients, with a mean age of 38.04 ± 11.03, experiencing an acute manic episode and receiving valproate sodium treatment for one week were randomly assigned to either the melatonin group or the placebo group. Both melatonin and a matched placebo were initiated at a dosage of 3 mg/day at bedtime for the first week and increased to 6 mg/day for the subsequent three weeks. The primary efficacy endpoint focused on evaluating the severity of manic symptoms using the Young Mania Rating Scale (YMRS) at enrollment and at weeks 1, 2, and 4 post-interventions. Additionally, as a secondary efficacy endpoint, the change in insomnia severity was assessed at the end of the study period using the Insomnia Severity Index (ISI) questionnaire.

Results

Analyses were conducted on an Intention-to-Treat (ITT) analysis dataset. Despite a significant decrease in mean Young Mania Rating Scale (YMRS) scores over the four-week study period in both treatment groups, melatonin exhibited a notably higher improvement in manic symptoms compared to the placebo (-value ≤ 0.001). By the end of week 4, patients receiving a placebo demonstrated a mean ± SD decrease in YMRS scores of -17.3 ± 4.75, while those treated with melatonin experienced a significantly more reduction, with a mean ± SD of -21.06 ± 5.92 (-value = 0.012). The proportion of responders, defined as patients with a ≥ 50% reduction in YMRS total score, and remitters, defined as those with an endpoint YMRS score ≤12, was also significantly higher in the melatonin-treated group compared to the placebo group. Furthermore, at the study endpoint, the melatonin group experienced a greater reduction in the mean ISI score compared to the placebo group (11.51 ± 3.07 8.97 ± 3.56; value < 0.001). Importantly, melatonin was well tolerated by the study patients at this dosage.

Conclusion

In summary, our study findings provide support for the use of melatonin as an adjunctive therapy in the treatment of acute bipolar mania. The positive outcomes observed warrant further investigations to replicate and extend these findings, contributing to a more comprehensive understanding of melatonin's role in managing bipolar disorder during manic episodes.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/npj/10.2174/0122103155307953240529111039
2024-06-06
2025-01-19

  • From This Site

    /content/journals/npj/10.2174/0122103155307953240529111039
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MiklowitzD.J. JohnsonS.L. Bipolar disorder.John Wiley & Sons Inc.2008
     [Google Scholar]
  2. Müller-OerlinghausenB. BerghöferA. BauerM. Bipolar disorder.Lancet2002359930224124710.1016/S0140‑6736(02)07450‑0 11812578
     [Google Scholar]
  3. BarnettJ.H. SmollerJ.W. The genetics of bipolar disorder.Neuroscience2009164133134310.1016/j.neuroscience.2009.03.080 19358880
     [Google Scholar]
  4. PintoJ.V. SarafG. KozickyJ. BeaulieuS. SharmaV. ParikhS.V. CervantesP. DaigneaultA. WaljiN. Kauer-Sant’AnnaM. YathamL.N. Remission and recurrence in bipolar disorder: The data from health outcomes and patient evaluations in bipolar disorder (HOPE-BD) study.J. Affect. Disord.202026815015710.1016/j.jad.2020.03.018 32174473
     [Google Scholar]
  5. RosenthalS.J. McCartyR. Switching winter and summer photoperiods in an animal model of bipolar disorder.Neuropsychopharmacology201944101677167810.1038/s41386‑019‑0337‑4 30787426
     [Google Scholar]
  6. McIntyreR.S. CalabreseJ.R. Bipolar depression: The clinical characteristics and unmet needs of a complex disorder.Curr. Med. Res. Opin.201935111993200510.1080/03007995.2019.1636017 31311335
     [Google Scholar]
  7. MillerS. Dell’OssoB. KetterT.A. The prevalence and burden of bipolar depression.J. Affect. Disord.2014169Suppl. 1S3S1110.1016/S0165‑0327(14)70003‑5 25533912
     [Google Scholar]
  8. KesslerR.C. McGonagleK.A. ZhaoS. NelsonC.B. HughesM. EshlemanS. WittchenH.U. KendlerK.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.Arch. Gen. Psychiatry199451181910.1001/archpsyc.1994.03950010008002 8279933
     [Google Scholar]
  9. GoodwinF. JamisonK. Manic-Depressive Illness. Bipolar Disorders and Recurrent Depression.OxfordOxford University Press2007
     [Google Scholar]
  10. GoodwinG. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for PsychopharmacologyJ. Psychopharmacol.2016306495553
     [Google Scholar]
  11. Antai-OtongD. Adverse drug reactions associated with antipsychotics, antidepressants, and mood stabilizers.Nurs. Clin. North Am.200338116117610.1016/S0029‑6465(02)00069‑5 12712677
     [Google Scholar]
  12. MathewsD.C. HenterI.D. ZarateC.A.Jr New drug developments for bipolar mania.Psychiatr. Times201229121919
     [Google Scholar]
  13. CassidyF. MurryE. ForestK. CarrollB.J. Signs and symptoms of mania in pure and mixed episodes.J. Affect. Disord.1998502-318720110.1016/S0165‑0327(98)00016‑0 9858078
     [Google Scholar]
  14. GoldA. SylviaL. The role of sleep in bipolar disorder.Nat. Sci. Sleep2016820721410.2147/NSS.S85754 27418862
     [Google Scholar]
  15. De CrescenzoF. EconomouA. SharpleyA.L. GormezA. QuestedD.J. Actigraphic features of bipolar disorder: A systematic review and meta-analysis.Sleep Med. Rev.201733586910.1016/j.smrv.2016.05.003 28185811
     [Google Scholar]
  16. BarbiniB. BenedettiF. ColomboC. DotoliD. BernasconiA. Cigala-FulgosiM. FloritaM. SmeraldiE. Dark therapy for mania: A pilot study.Bipolar Disord.2005719810110.1111/j.1399‑5618.2004.00166.x 15654938
     [Google Scholar]
  17. PandiperumalS. TrakhtI. SrinivasanV. SpenceD. MaestroniG. ZisapelN. CardinaliD. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways.Prog. Neurobiol.200885333535310.1016/j.pneurobio.2008.04.001 18571301
     [Google Scholar]
  18. BarrenetxeJ. DelagrangeP. MartínezJ.A. Physiological and metabolic functions of melatonin.J. Physiol. Biochem.2004601617210.1007/BF03168221 15352385
     [Google Scholar]
  19. AsarnowL.D. SoehnerA.M. HarveyA.G. Circadian rhythms and psychiatric illness.Curr. Opin. Psychiatry201326656657110.1097/YCO.0b013e328365a2fa 24060916
     [Google Scholar]
  20. MaldonadoM.D. ReiterR.J. Pérez-San-GregorioM.A. Melatonin as a potential therapeutic agent in psychiatric illness.Hum. Psychopharmacol.200924539140010.1002/hup.1032 19551767
     [Google Scholar]
  21. De CrescenzoF. LennoxA. GibsonJ.C. CordeyJ.H. StocktonS. CowenP.J. QuestedD.J. Melatonin as a treatment for mood disorders: A systematic review.Acta Psychiatr. Scand.2017136654955810.1111/acps.12755 28612993
     [Google Scholar]
  22. KennedyS.H. KutcherS.P. RalevskiE. BrownG.M. Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder.Psychiatry Res.1996632-321922210.1016/0165‑1781(96)02910‑1 8878318
     [Google Scholar]
  23. KennedyS.H. TigheS. McVEY, G.A.I.L.; Brown, G.M. Melatonin and cortisol “switches” during mania, depression, and euthymia in a drug-free bipolar patient.J. Nerv. Ment. Dis.1989177530030310.1097/00005053‑198905000‑00009 2708973
     [Google Scholar]
  24. LivianosL. SierraP. ArquesS. GarcíaA. RojoL. Is melatonin an adjunctive stabilizer?Psychiatry Clin. Neurosci.2012661828310.1111/j.1440‑1819.2011.02288.x 22250617
     [Google Scholar]
  25. BersaniG. GaraviniA. Melatonin add-on in manic patients with treatment resistant insomnia.Prog. Neuropsychopharmacol. Biol. Psychiatry200024218519110.1016/S0278‑5846(99)00097‑4 10800742
     [Google Scholar]
  26. MoghaddamH.S. BahmaniS. BayanatiS. MahdavinasaM. RezaeiF. AkhondzadehS. Efficacy of melatonin as an adjunct in the treatment of acute mania: A double-blind and placebo-controlled trial.Int. Clin. Psychopharmacol.2020352818810.1097/YIC.0000000000000298 31743233
     [Google Scholar]
  27. QuestedD.J. GibsonJ.C. SharpleyA.L. CordeyJ.H. EconomouA. De CrescenzoF. VoyseyM. LawsonJ. RendellJ.M. Al-TaiarH. LennoxA. AhmadF. GeddesJ.R. Melatonin in acute mania investigation (MIAMI‐UK). A randomized controlled trial of add‐on melatonin in bipolar disorder.Bipolar Disord.202123217618510.1111/bdi.12944 32474993
     [Google Scholar]
  28. AssociationA.P. Diagnostic and statistical manual of mental disorders (DSM-5®).American Psychiatric Pub.201310.1176/appi.books.9780890425596
     [Google Scholar]
  29. SheehanD.V. LecrubierY. SheehanK.H. AmorimP. JanavsJ. WeillerE. HerguetaT. BakerR. DunbarG.C. The mini-international neuropsychiatric interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.J. Clin. Psychiatry19985920Suppl. 202233 9881538
     [Google Scholar]
  30. YoungR.C. BiggsJ.T. ZieglerV.E. MeyerD.A. A rating scale for mania: Reliability, validity and sensitivity.Br. J. Psychiatry1978133542943510.1192/bjp.133.5.429 728692
     [Google Scholar]
  31. BarakatainM. Standardization, validity and reliability of young mania rating scale in Iran.J. Psychol.20072150166
     [Google Scholar]
  32. TohenM. JacobsT.G. GrundyS.L. McElroyS.L. BanovM.C. JanicakP.G. SangerT. RisserR. ZhangF. TomaV. FrancisJ. TollefsonG.D. BreierA. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study.Arch. Gen. Psychiatry200057984184910.1001/archpsyc.57.9.841 10986547
     [Google Scholar]
  33. BastienC. VallièresA. MorinC.M. Validation of the insomnia severity index as an outcome measure for insomnia research.Sleep Med.20012429730710.1016/S1389‑9457(00)00065‑4 11438246
     [Google Scholar]
  34. DastaniM. Effectiveness of drug therapy and behavioral therapy on chronic insomnia.Psychol. Med.2011
     [Google Scholar]
  35. GeoffroyP.A. Micoulaud FranchiJ.A. LopezR. SchroderC.M. The use of melatonin in adult psychiatric disorders: Expert recommendations by the French institute of medical research on sleep (SFRMS).Encephale201945541342310.1016/j.encep.2019.04.068 31248601
     [Google Scholar]
  36. ChenY. HongW. FangY. Role of biological rhythm dysfunction in the development and management of bipolar disorders: A review.Gen. Psychiatr.2020331e10012710.1136/gpsych‑2019‑100127 32090195
     [Google Scholar]
  37. GiglioL.M. MagalhãesP.V.S. KapczinskiN.S. WalzJ.C. KapczinskiF. Functional impact of biological rhythm disturbance in bipolar disorder.J. Psychiatr. Res.201044422022310.1016/j.jpsychires.2009.08.003 19758600
     [Google Scholar]
  38. NurnbergerJ.I.Jr AdkinsS. LahiriD.K. MayedaA. HuK. LewyA. MillerA. BowmanE.S. MillerM.J. RauL. SmileyC. Davis-SinghD. Melatonin suppression by light in euthymic bipolar and unipolar patients.Arch. Gen. Psychiatry200057657257910.1001/archpsyc.57.6.572 10839335
     [Google Scholar]
  39. PlanteD.T. WinkelmanJ.W. Sleep disturbance in bipolar disorder: Therapeutic implications.Am. J. Psychiatry2008165783084310.1176/appi.ajp.2008.08010077 18483132
     [Google Scholar]
  40. PerlmanC.A. JohnsonS.L. MellmanT.A. The prospective impact of sleep duration on depression and mania.Bipolar Disord.20068327127410.1111/j.1399‑5618.2006.00330.x 16696829
     [Google Scholar]
  41. EtainB. DumaineA. BellivierF. PaganC. FrancelleL. Goubran-BotrosH. MorenoS. DeshommesJ. MoustafaK. Le DudalK. MathieuF. HenryC. KahnJ.P. LaunayJ.M. MühleisenT.W. CichonS. BourgeronT. LeboyerM. JamainS. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder.Hum. Mol. Genet.201221184030403710.1093/hmg/dds227 22694957
     [Google Scholar]
  42. GeoffroyP.A. BoudebesseC. HenrionA. JamainS. HenryC. LeboyerM. BellivierF. EtainB. An ASMT variant associated with bipolar disorder influences sleep and circadian rhythms: A pilot study.Genes Brain Behav.201413329930410.1111/gbb.12103 24308489
     [Google Scholar]
  43. De BerardisD. MariniS. FornaroM. SrinivasanV. IasevoliF. TomasettiC. ValcheraA. PernaG. Quera-SalvaM.A. MartinottiG. di GiannantonioM. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.Int. J. Mol. Sci.2013146124581248310.3390/ijms140612458 23765220
     [Google Scholar]
  44. HallamK.T. OlverJ.S. NormanT.R. Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers.Neuropsychopharmacology20053071400140410.1038/sj.npp.1300739 15841104
     [Google Scholar]
  45. SeggieJ.O. WerstiukE.S. GrotaL. Lithium and circadian patterns of melatonin in the retina, hypothalamus, pineal and serum.Prog. Neuropsychopharmacol. Biol. Psychiatry1987112-332533410.1016/0278‑5846(87)90077‑7 2819953
     [Google Scholar]
  46. HallamK.T. OlverJ.S. HorganJ.E. McGrathC. NormanT.R. Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers.Int. J. Neuropsychopharmacol.20058225525910.1017/S1461145704004894 15850501
     [Google Scholar]
  47. Pandi-PerumalS.R. TrakhtI. SpenceD.W. SrinivasanV. DaganY. CardinaliD.P. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders.Nat. Clin. Pract. Neurol.20084843644710.1038/ncpneuro0847 18628753
     [Google Scholar]
  48. MilhietV. BoudebesseC. BellivierF. DrouotX. HenryC. LeboyerM. EtainB. Circadian abnormalities as markers of susceptibility in bipolar disorders.Front. Biosci. (Schol. Ed.)201461120137 24389266
     [Google Scholar]
  49. SteckertA.V. ValvassoriS.S. MorettiM. Dal-PizzolF. QuevedoJ. Role of oxidative stress in the pathophysiology of bipolar disorder.Neurochem. Res.20103591295130110.1007/s11064‑010‑0195‑2 20499165
     [Google Scholar]
  50. FriesG.R. Walss-BassC. BauerM.E. TeixeiraA.L. Revisiting inflammation in bipolar disorder.Pharmacol. Biochem. Behav.2019177121910.1016/j.pbb.2018.12.006 30586559
     [Google Scholar]
  51. AndersonG. MaesM. Local melatonin regulates inflammation resolution: A common factor in neurodegenerative, psychiatric and systemic inflammatory disorders.CNS Neurol. Disord. Drug Targets201413581782310.2174/1871527313666140711091400
     [Google Scholar]
  52. BiggioG. BiggioF. TalaniG. MostallinoM.C. AgugliaA. AgugliaE. PalaginiL. Melatonin: From neurobiology to treatment.Brain Sci.2021119112110.3390/brainsci11091121 34573143
     [Google Scholar]
  53. GeoffroyP. EtainB. FranchiJ.A. BellivierF. RitterP. Melatonin and melatonin agonists as adjunctive treatments in bipolar disorders.Curr. Pharm. Des.201521233352335810.2174/1381612821666150619093448 26088111
     [Google Scholar]
  54. RobertsonJ.M. TanguayP. Case study: The use of melatonin in a boy with refractory bipolar disorder.J. Am. Acad. Child Adolesc. Psychiatry199736682282510.1097/00004583‑199706000‑00020 9183138
     [Google Scholar]
  55. NierenbergA.A. Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression.Psychother. Psychosom.200978639139310.1159/000235985 19738411
     [Google Scholar]
  56. LeibenluftE. Feldman-NaimS. TurnerE.H. WehrT.A. RosenthalN.E. Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder.J. Clin. Psychiatry199758938338810.4088/JCP.v58n0902 9378688
     [Google Scholar]
  57. Romo-NavaF. Alvarez-Icaza GonzálezD. Fresán-OrellanaA. Saracco AlvarezR. Becerra-PalarsC. MorenoJ. Ontiveros UribeM.P. BerlangaC. HeinzeG. BuijsR.M. Melatonin attenuates antipsychotic metabolic effects: An eight‐week randomized, double‐blind, parallel‐group, placebo‐controlled clinical trial.Bipolar Disord.201416441042110.1111/bdi.12196 24636483
     [Google Scholar]
  58. KishiT. NomuraI. SakumaK. KitajimaT. MishimaK. IwataN. Melatonin receptor agonists—ramelteon and melatonin—for bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.Neuropsychiatr. Dis. Treat.2019151479148610.2147/NDT.S198899 31239683
     [Google Scholar]
  59. PozaJ. Melatonin in sleep disorders.Neurologia2020 36064286
     [Google Scholar]
  60. AndersenL.P.H. GögenurI. RosenbergJ. ReiterR.J. The safety of melatonin in humans.Clin. Drug Investig.201636316917510.1007/s40261‑015‑0368‑5 26692007
     [Google Scholar]
  61. ClayE. FalissardB. MooreN. ToumiM. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries.Eur. J. Clin. Pharmacol.201369411010.1007/s00228‑012‑1424‑1 23114457
     [Google Scholar]
  62. PatelT. KurdiM. A comparative study between oral melatonin and oral midazolam on preoperative anxiety, cognitive, and psychomotor functions.J. Anaesthesiol. Clin. Pharmacol.2015311374310.4103/0970‑9185.150534 25788771
     [Google Scholar]
  63. NaguibM. SamarkandiA.H. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: A double-blinded, placebo-controlled study.Anesth. Analg.2000912473479 10910871
     [Google Scholar]
  64. SumsuzzmanD.M. ChoiJ. JinY. HongY. Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials.Neurosci. Biobehav. Rev.202112745947310.1016/j.neubiorev.2021.04.034 33957167
     [Google Scholar]
  65. AranarochanaA. Melatonin ameliorates valproic acid-induced neurogenesis impairment: The role of oxidative stress in adult rats.Oxid. Med. Cell. Longev.202111010.1155/2021/9997582
     [Google Scholar]
  66. MostafaviA. SolhiM. MohammadiM.R. HamediM. KeshavarziM. AkhondzadehS. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: A randomized double-blind placebo-controlled trial.Acta Med. Iran.20145210734739 25369006
     [Google Scholar]
  67. ModabberniaA. HeidariP. SoleimaniR. SobhaniA. RoshanZ.A. TaslimiS. AshrafiM. ModabberniaM.J. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study.J. Psychiatr. Res.20145313314010.1016/j.jpsychires.2014.02.013 24607293
     [Google Scholar]
  68. TuftC. MatarE. Menczel SchrireZ. GrunsteinR.R. YeeB.J. HoyosC.M. Current insights into the risks of using melatonin as a treatment for sleep disorders in older adults.Clin. Interv. Aging202318495910.2147/CIA.S361519 36660543
     [Google Scholar]
/content/journals/npj/10.2174/0122103155307953240529111039
Loading
Add-on Therapy with Melatonin in the Acute Bipolar Mania Treatment: Results of a Randomized, Placebo-controlled Trial
Natural Products Journal, The 15, E060624230788 (2025); https://doi.org/10.2174/0122103155307953240529111039
/content/journals/npj/10.2174/0122103155307953240529111039
/content/journals/npj/10.2174/0122103155307953240529111039
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): antioxidant; Bipolar disorder; insomnia; manic phase; melatonin; oxidative stress

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test